Table 1

Baseline demographic and clinical characteristics

CharacteristicsMTX (n=69)TwHF (n=69)TwHF+MTX (n=69)
Age (SD), years51.0 (10.3)51.3 (8.3)50.6 (8.6)
Women, n (%)59 (85.5)56 (81.2)55 (79.7)
Weight (SD), kg61.0 (11.5)60.8 (11.0)61.9 (10.1)
Disease duration (SD), months58.8 (88.7)61.9 (81.9)76.3 (92.3)
TJC (SD), n16.2 (8.3)13.8 (7.2)15.4 (8.2)
SJC (SD), n9.1 (6.0)8.9 (6.1)9.0 (6.6)
Patient's assessment of pain (SD), mm71.8 (22.5)68.5 (25.5)70.6 (20.8)
Patient's global assessment of disease activity (SD), mm68.0 (24.6)65.5 (23.6)66.1 (20.9)
Physician's global assessment of disease activity (SD), mm62.8 (23.5)60.0 (23.7)61.7 (23.0)
HAQ (SD)1.53 (0.85)1.33 (0.92)1.43 (0.86)
SF-36 (SD)237.8 (127.0)292.6 (155.3)279.1 (153.4)
ESR (SD), mm/h54.0 (28.0)45.1 (24.6)52.7 (25.9)
CRP (SD), mg/L38.1 (40.3)27.3 (25.0)30.1 (28.7)
Anti-CCP* positive, n (%)55 (79.7)53 (76.8)54 (78.3%)
RF* positive, n (%)53 (76.8)56 (81.2)53 (76.8%)
DAS28-ESR (SD)6.62 (1.31)6.22 (1.28)6.45 (1.36)
DAS28-CRP (SD)6.05 (1.24)5.60 (1.24)5.73 (1.30)
cDAI (SD)38.5 (17.0)34.4 (15.7)35.7 (17.4)
Steroid used, n (%)11 (15.9)15 (21.7)10 (14.5)
  • Data are presented as mean (SD) or n (%).

  • *RF was measured by immunonephelometry with a cut-off value of 20 U/mL. Anti-CCP was measured using a commercially available second-generation ELISA kit (Euro-Diagnostica, Malmo, Sweden) with a cut-off value of 25 U/mL.

  • Anti-CCP, anti-cyclic citrullinated peptide antibody; cDAI, clinical Disease Activity Index; CRP, C-reactive protein; DAS28, 28-joint count Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MTX, methotrexate; RF, rheumatoid factor; SF-36, the 36-item Short-Form Health Survey questionnaire; SJC, swollen joint count; TJC, tender joint count; TwHF, Tripterygium wilfordii Hook F.